Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome.

BACKGROUND

Abiraterone acetate (abiraterone) combined with prednisone is a standard of care in metastatic castration-resistant prostate cancer. Recently, benefit in overall survival was reported in metastatic castration-sensitive prostate cancer also, and an extension of indication has been granted. Abiraterone is seldom associated with liver toxicity. The clinical management and the outcome of patients with transaminase increase while on abiraterone have not been described.

PATIENTS AND METHOD

We identified 25 men with metastatic prostate cancer and liver function test disorders occurring while on abiraterone treatment from December 2009 to September 2017 in three oncology centres in France.

RESULTS

Forty-six liver disorder events occurred in 25 patients while on abiraterone treatment. The median age at liver function test increase was 67 (55-85) years. The incidence of aspartate aminotransférase (AST) (24 events) and that of alanine aminotransférase (ALT) (22 events) increases were similar. Liver toxicity was of grade 1, 2 and 3 (Common Terminology Criteria for Adverse Events. version 4) in 7 (32%), 6 (27%) and 9 (41%) patients for ALT, and in 12 (50%), 6 (25%) and 6 (25%) for AST, respectively. The median time from abiraterone initiation to the detection of liver toxicity was 7.1 (4-95) weeks. The median time from highest ALT/AST increase to normalisation was 6.2 [2-14] weeks. In 13 patients (52%), liver tests spontaneously returned to baseline values, while abiraterone was continued at full dose.

CONCLUSION

Liver function test increase is a rare event that typically occurs within the first two months on abiraterone. Most patients experience normalisation of the tests, either spontaneously or after dose reduction/discontinuation.

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement E.C. declared having received personal fees from Ipsen, Sanofi, BMS and Pfizer. G.B. declared having received consulting fees from Janssen-Cilag and Sanofi. Y.L. has received honoraria from Sanofi, Janssen, MSD, Roche, BMS, AstraZeneca, Astellas and Seattle Genetics; has received grants from Sanofi, Janssen and MSD and has been an investigator in trials sponsored by MSD, Roche, Astellas, Janssen, Nektar, BMS, Pfizer, Incyte, Clovis, AstraZeneca and Seattle Genetics. L.A. declared serving consulting or advisory role in Novartis, Amgen (Inst), Bristol-Myers Squibb, Bristol-Myers Squibb (Inst), Ipsen (Inst), Roche (Inst), Novartis (Inst), Pfizer (Inst), Astellas Pharma (Inst) and Merck (Inst). C.M. reported receiving grants and personal fees and is a principal investigator/co-principal investigator for Amgen, Astella, AstraZeneca, Bayer, BeiGene, BMS, Genentech, Janssen, Lilly, MedImmune, MSD, Novartis, Pfizer, Roche, Sanofi, Orion and Abbvie. J.A. has received grants and honoraria from AstraZeneca, Roche/Genentech, Novartis, Ipsen and Jansen. O.H. declared having received personal fees from IPSEN, Janssen, Bayer, BMS and Sanofi. S.C. declares serving a consultant role for Janssen, Roche and Merck; that he has received research funding from Astellas and Roche and that he has been beneficiant of travel support from Janssen, Roche and Astellas. K.F. declared having received fees for participation to advisory boards or lectures for Amgen, Astellas, Bayer, Janssen-Cilag, Orion and Sanofi. G.M., P.L. and E.C. declared no disclosure.